Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can estrogen boost the 'Love Hormone' in a rare condition?

NCT ID NCT06460948

Knowledge-focused Sponsor: Elizabeth Austen Lawson Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tested whether a single dose of oral estrogen-progestin can raise oxytocin levels in people with arginine vasopressin deficiency (AVD), a rare condition that also causes low oxytocin. Researchers compared 28 adults—some with AVD and some healthy—to see if oxytocin responses differ and if lower oxytocin relates to anxiety, depression, or quality of life. The goal is to better understand the link between hormones and emotional health in AVD.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Estrogen-progestin (norethindrone acetate-ethinyl estradiol)
What this could lead to
If successful, this could help understand oxytocin deficiency in AVD and point toward future treatments for related anxiety, depression, or social difficulties.
What could go wrong
This is a very early, small pilot study with only 28 participants. Results may not apply to broader populations, and the single-dose design limits conclusions about long-term effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

28 people

The number who actually took part.

Started

Nov 2024

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * AVD Group: Adults 18-65 years old Arginine-vasopressin deficiency Stable pituitary hormone replacement * Healthy Control Group Adults 16-65 years old Exclusion Criteria for all participants: * History of pulmonary embolism, deep vein thrombosis, breast/endometrial cancer, stroke, transient ischemic attack, myocardial infarction, angina pectoris, or peripheral artery disease * Pregnancy or breastfeeding within last 8 weeks * Any significant illness or condition that the investigator determines could interfere with study participation, data collection, or safety

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arginine vasopressin deficiency are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Diabetes Insipidus, Neurogenic neurohypophyseal diabetes insipidus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arginine vasopressin deficiency Oxytocin deficiency

Contacts and locations

Locations

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.